



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/647,270	12/21/2000	W. Edward Robinson Jr.	82351.0008	5369

7590

04/09/2002

STEFAN J. KIRCHANSKI
CROSBY, HEAFEY, ROACH & MAY
1901 AVENUE OF THE STARS
SUITE 700
LOS ANGELES, CA 90067

EXAMINER

TRAVERS, RUSSELL S

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 04/09/2002

7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/647,270

Applicant(s)
Robinson et al

Examiner
Russell Travers

Art Unit
1617



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on _____.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-23 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claims 1-23 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- *See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892)
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____
- 18) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 19) ☐ Notice of Informal Patent Application (PTO-152)
- 20) ☐ Other:

Art Unit:

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1-7, drawn to an anti-HIV therapeutic method employing various reverse transcriptase inhibitors, protease inhibitors and Integrase inhibitors administered concomitantly.

II. Claims 8-14, drawn to anti-HIV therapeutic compositions employing various reverse transcriptase inhibitors, protease inhibitors and Integrase inhibitors administered concomitantly.

III. Claim 15, drawn to various anti-HIV therapeutic Integrase inhibitor compounds.

IV. Claims 16-23, drawn to anti-HIV therapeutic compounds possessing a C₂-C₆ carbon chain backbone.

Claims contained in Groups I-IV are directed to a plurality of patentably distinct inventive species. Applicants are required under 37 CFR 1.499 to elect a distinct inventive species from the selected group for examination on the merits. Additionally, Applicants are required to provide a claim directed to this inventive species, or identify a claim directed to this elected species, even though the requirement is traversed.

The above delineated inventions differ as distinct therapeutic methods, therapeutic compositions, and therapeutic compounds. The grouped inventions are patentably distinct, a reference which would anticipate, or make obvious, any invention from groups I-IV would not necessarily obviate, or anticipate, the inventions in any

Art Unit:

other group. The searches are not co-inclusive as indicated by the diverse nature of the subject matter. Those proposed inventions recited herein are only linked by the presented specification; with each invention requiring separate, distinct search, and consideration. One skilled in the art would readily practice the invention of one of the above groups with out infringing and/or practicing the invention of another group. The subject matter is unique and has acquired a separate status in the art and is fully capable of supporting separate patents. For the foregoing reasons restriction is proper for examination purposes.

The instant application was filed under 35 USC 371, requiring restriction by unity of invention. The authority for this restriction practice is found in 37 CFR 1.499. To restrict a case filed under 35 USC 371, the Examiner need not consider the burden posed by examining additional inventions; although such burden is present in the instant case.

Patent Cooperation Rules (PCT) Rules 13.1 and 13.2 permit in a single application only one invention. Thus, an application presenting more than one invention, as in the instant case, is appropriately restricted for lack of unity.


The grouped inventions are patentably distinct, a reference which would anticipate, or make obvious, any invention from groups I-V would not necessarily obviate, or anticipate, the inventions in any other group. The searches are not co-inclusive as indicated by the diverse nature of the subject matter, thus, would represent

Art Unit:

an undue burden on Examiner. One skilled in the art would readily practice the invention of one of the above groups with out infringing and or practicing the invention of another group. The subject matter is unique and has acquired a separate status in the art and is fully capable of supporting separate patents. For the foregoing reasons restriction is proper for examination purposes.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variations or clearly admit on the record that this is the case. In either instance, if Examiner finds one of the inventions unpatentable over the prior art, the evidence may be used in a rejection under 35 USC 103 of the other invention.

Any inquiry concerning this communication should be directed to Russell Travers at telephone number (703) 308-4603.



**Russell Travers
Primary Examiner
Art Unit 1617**